- The document is an investor presentation that provides an overview of Vocera Communications, including forward-looking statements and information about the company's market opportunity, platform, recent wins, financial highlights, and revenue breakdown.
- Vocera is shifting the market toward its software-centric platform and complete solutions, and recent large wins validate its sales strategy of targeting enterprise-wide deployments.
- The company has seen strong revenue growth, expanding profitability, and a diversified revenue model with over 50% of revenues being recurring.
The presentation discusses Vocera's investor opportunity, highlighting:
1) The large healthcare market is shifting toward Vocera's communication platform as the market leader with a compelling ROI.
2) Recent large wins validate the company's sales strategy and software acquisitions are extending its platform.
3) Vocera is accelerating its operating leverage and targeting operating leverage models with revenue growth of 10-11% and adjusted EBITDA margins expanding to over 10%.
Vocera presented its investor presentation for May 2018 which included the following key points:
1) Vocera highlighted its large market opportunity in healthcare communications and the shift toward its software-centric platform and solutions.
2) Financial results showed continued revenue growth of 10% in Q1 2018 and 26% in 2017, with recurring revenue streams making up over 50% of total revenue.
3) Vocera is targeting operating leverage through reducing operating expenses as a percentage of revenue, with the goal of increasing adjusted EBITDA margins.
The document provides an investor presentation for Vocera Communications. It discusses Vocera's opportunity in the large and shifting healthcare communications market, recent platform wins that validate its sales strategy, and financial highlights showing growing revenue, expanding profitability, and accelerating operating leverage. Vocera aims to achieve a target operating model with reduced costs as a percentage of revenue.
The document discusses Vocera Communications' investor presentation. It highlights that:
1) The large market is shifting toward Vocera's platform as the market leader with compelling ROI and large wins validating its sales strategy.
2) Vocera is expanding its platform through software acquisitions and accelerating its operating leverage.
3) It provides forward-looking statements and non-GAAP financial measures along with accompanying risks and disclaimer information.
The document provides an investor presentation for Vocera Communications. It contains the following key points:
1) Vocera provides forward-looking statements about market shifting toward their products, accelerating operating leverage, and potential future products. However, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
2) Vocera has strategically evolved from a badge-centric point product to a software-centric complete communication platform for hospitals. This allows them to pursue larger hospital-wide deals.
3) Vocera's communication platform has demonstrated compelling return on investment for customers through improved operational efficiency, patient safety and satisfaction.
The document is an investor presentation for Vocera Communications that contains forward-looking statements and information. It discusses Vocera's market opportunity, strategic evolution towards a software-centric platform, examples of return on investment for customers, recent platform wins, competitive landscape, vision for a real-time health system, and financial highlights including revenue and adjusted EBITDA growth.
Vocera investordeck september 2018 webvocera2016ir
- The document is an investor presentation from Vocera Communications that discusses the company's market opportunity, strategy, financial highlights, and operating model.
- It notes Vocera's large and growing market opportunity in healthcare communication, recent platform wins that validate its strategy, and accelerating operating leverage and profitability.
- Financial highlights include 26% revenue growth in 2017, expanding adjusted EBITDA margins, and a diversified revenue mix with over 50% recurring revenues.
Vocera investordeck august 2018 web versionvocera2016ir
The document provides an investor presentation for Vocera Communications. It includes:
1) Forward-looking statements that are based on management's beliefs and assumptions and involve known and unknown risks.
2) Financial highlights showing revenue growth, expanding profitability, and a diversified revenue model with over 50% of revenues being recurring.
3) A target operating model to drive further operating leverage and value through increasing software mix and decreasing sales and marketing expenses as a percentage of revenue.
The presentation discusses Vocera's investor opportunity, highlighting:
1) The large healthcare market is shifting toward Vocera's communication platform as the market leader with a compelling ROI.
2) Recent large wins validate the company's sales strategy and software acquisitions are extending its platform.
3) Vocera is accelerating its operating leverage and targeting operating leverage models with revenue growth of 10-11% and adjusted EBITDA margins expanding to over 10%.
Vocera presented its investor presentation for May 2018 which included the following key points:
1) Vocera highlighted its large market opportunity in healthcare communications and the shift toward its software-centric platform and solutions.
2) Financial results showed continued revenue growth of 10% in Q1 2018 and 26% in 2017, with recurring revenue streams making up over 50% of total revenue.
3) Vocera is targeting operating leverage through reducing operating expenses as a percentage of revenue, with the goal of increasing adjusted EBITDA margins.
The document provides an investor presentation for Vocera Communications. It discusses Vocera's opportunity in the large and shifting healthcare communications market, recent platform wins that validate its sales strategy, and financial highlights showing growing revenue, expanding profitability, and accelerating operating leverage. Vocera aims to achieve a target operating model with reduced costs as a percentage of revenue.
The document discusses Vocera Communications' investor presentation. It highlights that:
1) The large market is shifting toward Vocera's platform as the market leader with compelling ROI and large wins validating its sales strategy.
2) Vocera is expanding its platform through software acquisitions and accelerating its operating leverage.
3) It provides forward-looking statements and non-GAAP financial measures along with accompanying risks and disclaimer information.
The document provides an investor presentation for Vocera Communications. It contains the following key points:
1) Vocera provides forward-looking statements about market shifting toward their products, accelerating operating leverage, and potential future products. However, forward-looking statements involve risks and uncertainties that could cause actual results to differ materially.
2) Vocera has strategically evolved from a badge-centric point product to a software-centric complete communication platform for hospitals. This allows them to pursue larger hospital-wide deals.
3) Vocera's communication platform has demonstrated compelling return on investment for customers through improved operational efficiency, patient safety and satisfaction.
The document is an investor presentation for Vocera Communications that contains forward-looking statements and information. It discusses Vocera's market opportunity, strategic evolution towards a software-centric platform, examples of return on investment for customers, recent platform wins, competitive landscape, vision for a real-time health system, and financial highlights including revenue and adjusted EBITDA growth.
Vocera investordeck september 2018 webvocera2016ir
- The document is an investor presentation from Vocera Communications that discusses the company's market opportunity, strategy, financial highlights, and operating model.
- It notes Vocera's large and growing market opportunity in healthcare communication, recent platform wins that validate its strategy, and accelerating operating leverage and profitability.
- Financial highlights include 26% revenue growth in 2017, expanding adjusted EBITDA margins, and a diversified revenue mix with over 50% recurring revenues.
Vocera investordeck august 2018 web versionvocera2016ir
The document provides an investor presentation for Vocera Communications. It includes:
1) Forward-looking statements that are based on management's beliefs and assumptions and involve known and unknown risks.
2) Financial highlights showing revenue growth, expanding profitability, and a diversified revenue model with over 50% of revenues being recurring.
3) A target operating model to drive further operating leverage and value through increasing software mix and decreasing sales and marketing expenses as a percentage of revenue.
- The document is an investor presentation from Vocera Communications that provides an overview of the company's business, strategy, financials, and outlook.
- It highlights Vocera's large and growing market opportunity in healthcare communication, its platform strategy and software focus, and recent large customer wins that validate its approach.
- Financial results have exceeded expectations with 10% revenue growth in Q1 2018 and operating leverage is driving expanding profitability and cash flow, with adjusted EBITDA of $16.4 million in 2017.
The document discusses Vocera Communications' investor presentation from June 2018. It provides forward-looking statements regarding the market shifting toward Vocera, accelerating operating leverage, and potential future products and services. It also notes large market opportunities in the US and globally, recent platform wins validating their strategy, and a software platform that could expand into areas like voice assistants and real-time location systems. Financial highlights show growing revenue and adjusted EBITDA margins.
This presentation provides an overview of MedReleaf's business and operations. It discusses MedReleaf's position as the largest medical cannabis producer in Canada with an 81% market share. It highlights MedReleaf's rapid revenue growth, strong profit margins, and leadership in quality assurance. The presentation also outlines MedReleaf's expansion plans, focus on ongoing innovation, and growth opportunities in new medical cannabis products, the potential recreational market, and international expansion.
The document is an investor presentation for Vocera Communications covering Q4 2017 financial results and the company's strategy and market opportunity. It summarizes that Vocera exceeded expectations in Q4 with 26% revenue growth and 44% software growth. It also discusses the company's transition to a software-centric model, focus on larger enterprise deals, expanding profitability, and operating leverage goals to reduce expenses as a percentage of revenue.
MedReleaf is a Canadian licensed producer of medical cannabis with a market capitalization of $890 million. It has the largest market share of the Canadian medical cannabis market at 82%. The presentation discusses MedReleaf's strategy of focusing on quality, innovation, and profitability to establish itself as the standard in the medical cannabis industry. It highlights the company's expansion plans, new product development, and growth opportunities in medical cannabis in Canada and international markets.
CanniMed Therapeutics Inc. is a leader in the Canadian medical cannabis industry and the first mover in international markets. It has a 15-year history of growing pharmaceutical-grade cannabis and is well positioned for growth through new distribution channels in Canada, increasing production capacity, and pursuing exports to multiple countries. Recent developments include strong Q3 2017 results, entering Canada's first pharmacy distribution agreement, and commencing an expansion of its Cannabis Oils Facility.
This presentation discusses MedReleaf's position as the leading Canadian medical cannabis producer. It highlights MedReleaf's quality assurance processes, patient-centric approach, analytical operations, and ongoing innovation in producing premium cannabis. MedReleaf also discusses its market leading position with 82% market share, low production costs of $1.49 per gram, and high adjusted product contribution margins of 19%. The presentation outlines MedReleaf's expansion plans and growth opportunities in medical, new products, recreational, and international markets.
This investor presentation by MedReleaf provides the following information in 3 sentences:
MedReleaf is a Canadian licensed producer of medical cannabis with a market share of 82% of the total Canadian medical cannabis market. They have a low-cost production model with a cash cost per gram of $1.46 and grams produced per square foot of 300. MedReleaf is pursuing an expansion strategy through increasing production capacity, developing new product lines, entering international markets, and potential opportunities in the recreational cannabis market.
- Verisk reported strong revenue and earnings growth in 1Q2018 driven by organic growth in insurance as well as recent acquisitions. Revenue was up 16% while EBITDA grew 9%.
- The insurance segment performed particularly well with 8.8% organic revenue growth and 9.7% organic EBITDA growth. Claims solutions and underwriting/rating solutions both saw high single-digit organic constant currency growth.
- While energy and specialized markets saw lower organic growth and margin decline from increased investment, financial services delivered steady growth with strengthening margins.
The document discusses Verisk's global opportunities in the insurance industry. It outlines Verisk's vision and solutions for insurance, including recent acquisitions that have expanded its international platform. The document also analyzes target international markets and growth opportunities based on market dynamics and priorities. Finally, it discusses Verisk's global presence and organized approach to succeed internationally.
Henry Schein will spin off and merge its animal health business with Vets First Choice, creating a new animal health innovator called Vets First Corp. The transaction will provide strategic benefits to both companies by allowing Henry Schein to focus on dentistry and medicine, while positioning Vets First Corp. for growth in the veterinary market through an integrated technology-enabled platform. The transaction is expected to close by the end of 2018.
IntelGenX Investor Presentation June 5, 2017ItelGenx
- IntelGenx Corp. is a drug delivery company focused on oral thin film technologies.
- They have developed a proprietary drug delivery platform called Tri-Layer technology to improve the speed and efficiency of drug absorption through the oral mucosa.
- The presentation provides an overview of IntelGenx's management team, facilities, product pipeline, and financial information to investors considering an investment in the company.
This presentation provides an overview of Vocera Communications for investors. It discusses Vocera's transition from a badge-centric point product to a software-centric complete communication solution. It highlights Vocera's large market opportunity in healthcare, recent platform wins, and strategy to accelerate growth and profitability. Financials show growing revenue, expanding adjusted EBITDA margins, and a diversifying revenue mix with over 50% recurring revenues.
- Catasys provides an integrated virtual healthcare program called OnTrak that uses predictive analytics and outreach to identify and enroll high-cost members with behavioral health issues.
- OnTrak provides a 52-week treatment program that combines medical, pharmacological and psychosocial treatments to reduce costs by an average of 50% for enrolled members.
- Catasys has national agreements with several leading health plans covering over 7.5 million lives and is currently enrolling participants in 18 states.
The document is an investor presentation for Vocera Communications covering Q1 2018 financial results and outlook:
- Q1 revenue grew 10% year-over-year to $40.2 million, exceeding expectations, driven by 41% software revenue growth. Adjusted EBITDA was $1.8 million.
- For full year 2017, revenue increased 27% to $162.5 million with software revenue up 36%. Adjusted EBITDA reached $13.1 million.
- The company has a solid customer base and value proposition with a 95%+ software maintenance renewal rate and strong competitive win rate. Profitability and cash flow are expanding.
Verisk provides forward-looking statements and notes regarding non-GAAP financial measures in its investor materials. The statements relate to future events or financial performance that involve risks and uncertainties. The notes provide supplemental non-GAAP financial information and explain why the company believes these measures provide useful information to investors. Verisk has a strong track record of revenue growth, leading margins, and returning capital to shareholders through share repurchases and acquisitions.
Verisk Analytics held an investor day on December 1, 2015 to discuss its strategy and growth opportunities. The presentation included forward-looking statements and notes on the use of non-GAAP financial measures. It outlined Verisk's core competencies of large-scale data integration, multi-tier imaging, geo-location capabilities, stochastic modeling, and localization. Verisk believes these competencies combined with its unique data assets, domain expertise, and customer relationships position it for continued growth. Wood Mackenzie CEO Stephen Halliday then introduced Wood Mackenzie and how it complements Verisk in the energy and natural resources sectors.
The document discusses Verisk's global opportunities in the insurance industry. It highlights Verisk's focus on growing globally through organic opportunities and acquisitions. Verisk has a global team organized to succeed and pursues growth opportunities through products like Sequel and tuck-in acquisitions. Verisk is well positioned for future global growth in the insurance industry.
This document provides an investor presentation by Asanko Gold Inc. It summarizes the company's world-class asset base in Ghana, which includes over 7.9 million ounces of measured and indicated gold resources across six deposits. It highlights the company's successful construction and start-up of its mining operations, which are exceeding production guidance. The presentation outlines Asanko's plans for further near-term organic growth through exploration success and a phased expansion to increase annual gold production to over 450,000 ounces per year by 2022.
- Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies for central nervous system indications.
- They are developing novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) for indications like Tourette Syndrome and Mild Cognitive Impairment.
- For Tourette Syndrome, they are combining THC with PEA in a proprietary combination therapy called THX-TS01 that has begun Phase II clinical trials based on a 505(b)(2) regulatory pathway.
- For Mild Cognitive Impairment, they are developing an "Ultra-Low Dose THC" therapy called THX-ULD
Vocera investordeck may 12 2017 needhamvocera2016ir
The document discusses Vocera's investor review presentation. It notes that Vocera sees significant growth opportunities through expanding into new clinical areas, new user types, and international markets. It also highlights Vocera's strong financial performance in recent years with recurring revenue growing to 60% of sales and adjusted EBITDA margins expanding. The presentation aims to showcase Vocera as an attractive investment due to its large market opportunity and ability to leverage its operating model.
The document provides an investor review for Vocera Communications. It discusses Vocera's position as a leader in clinical communication and workflow solutions. It highlights Vocera's growth opportunities through continued customer and market expansion. Vocera aims to simplify healthcare professionals' work through its secure communication platform and integration capabilities. The review outlines Vocera's strong financial performance with recurring revenue streams and expanding profitability.
- The document is an investor presentation from Vocera Communications that provides an overview of the company's business, strategy, financials, and outlook.
- It highlights Vocera's large and growing market opportunity in healthcare communication, its platform strategy and software focus, and recent large customer wins that validate its approach.
- Financial results have exceeded expectations with 10% revenue growth in Q1 2018 and operating leverage is driving expanding profitability and cash flow, with adjusted EBITDA of $16.4 million in 2017.
The document discusses Vocera Communications' investor presentation from June 2018. It provides forward-looking statements regarding the market shifting toward Vocera, accelerating operating leverage, and potential future products and services. It also notes large market opportunities in the US and globally, recent platform wins validating their strategy, and a software platform that could expand into areas like voice assistants and real-time location systems. Financial highlights show growing revenue and adjusted EBITDA margins.
This presentation provides an overview of MedReleaf's business and operations. It discusses MedReleaf's position as the largest medical cannabis producer in Canada with an 81% market share. It highlights MedReleaf's rapid revenue growth, strong profit margins, and leadership in quality assurance. The presentation also outlines MedReleaf's expansion plans, focus on ongoing innovation, and growth opportunities in new medical cannabis products, the potential recreational market, and international expansion.
The document is an investor presentation for Vocera Communications covering Q4 2017 financial results and the company's strategy and market opportunity. It summarizes that Vocera exceeded expectations in Q4 with 26% revenue growth and 44% software growth. It also discusses the company's transition to a software-centric model, focus on larger enterprise deals, expanding profitability, and operating leverage goals to reduce expenses as a percentage of revenue.
MedReleaf is a Canadian licensed producer of medical cannabis with a market capitalization of $890 million. It has the largest market share of the Canadian medical cannabis market at 82%. The presentation discusses MedReleaf's strategy of focusing on quality, innovation, and profitability to establish itself as the standard in the medical cannabis industry. It highlights the company's expansion plans, new product development, and growth opportunities in medical cannabis in Canada and international markets.
CanniMed Therapeutics Inc. is a leader in the Canadian medical cannabis industry and the first mover in international markets. It has a 15-year history of growing pharmaceutical-grade cannabis and is well positioned for growth through new distribution channels in Canada, increasing production capacity, and pursuing exports to multiple countries. Recent developments include strong Q3 2017 results, entering Canada's first pharmacy distribution agreement, and commencing an expansion of its Cannabis Oils Facility.
This presentation discusses MedReleaf's position as the leading Canadian medical cannabis producer. It highlights MedReleaf's quality assurance processes, patient-centric approach, analytical operations, and ongoing innovation in producing premium cannabis. MedReleaf also discusses its market leading position with 82% market share, low production costs of $1.49 per gram, and high adjusted product contribution margins of 19%. The presentation outlines MedReleaf's expansion plans and growth opportunities in medical, new products, recreational, and international markets.
This investor presentation by MedReleaf provides the following information in 3 sentences:
MedReleaf is a Canadian licensed producer of medical cannabis with a market share of 82% of the total Canadian medical cannabis market. They have a low-cost production model with a cash cost per gram of $1.46 and grams produced per square foot of 300. MedReleaf is pursuing an expansion strategy through increasing production capacity, developing new product lines, entering international markets, and potential opportunities in the recreational cannabis market.
- Verisk reported strong revenue and earnings growth in 1Q2018 driven by organic growth in insurance as well as recent acquisitions. Revenue was up 16% while EBITDA grew 9%.
- The insurance segment performed particularly well with 8.8% organic revenue growth and 9.7% organic EBITDA growth. Claims solutions and underwriting/rating solutions both saw high single-digit organic constant currency growth.
- While energy and specialized markets saw lower organic growth and margin decline from increased investment, financial services delivered steady growth with strengthening margins.
The document discusses Verisk's global opportunities in the insurance industry. It outlines Verisk's vision and solutions for insurance, including recent acquisitions that have expanded its international platform. The document also analyzes target international markets and growth opportunities based on market dynamics and priorities. Finally, it discusses Verisk's global presence and organized approach to succeed internationally.
Henry Schein will spin off and merge its animal health business with Vets First Choice, creating a new animal health innovator called Vets First Corp. The transaction will provide strategic benefits to both companies by allowing Henry Schein to focus on dentistry and medicine, while positioning Vets First Corp. for growth in the veterinary market through an integrated technology-enabled platform. The transaction is expected to close by the end of 2018.
IntelGenX Investor Presentation June 5, 2017ItelGenx
- IntelGenx Corp. is a drug delivery company focused on oral thin film technologies.
- They have developed a proprietary drug delivery platform called Tri-Layer technology to improve the speed and efficiency of drug absorption through the oral mucosa.
- The presentation provides an overview of IntelGenx's management team, facilities, product pipeline, and financial information to investors considering an investment in the company.
This presentation provides an overview of Vocera Communications for investors. It discusses Vocera's transition from a badge-centric point product to a software-centric complete communication solution. It highlights Vocera's large market opportunity in healthcare, recent platform wins, and strategy to accelerate growth and profitability. Financials show growing revenue, expanding adjusted EBITDA margins, and a diversifying revenue mix with over 50% recurring revenues.
- Catasys provides an integrated virtual healthcare program called OnTrak that uses predictive analytics and outreach to identify and enroll high-cost members with behavioral health issues.
- OnTrak provides a 52-week treatment program that combines medical, pharmacological and psychosocial treatments to reduce costs by an average of 50% for enrolled members.
- Catasys has national agreements with several leading health plans covering over 7.5 million lives and is currently enrolling participants in 18 states.
The document is an investor presentation for Vocera Communications covering Q1 2018 financial results and outlook:
- Q1 revenue grew 10% year-over-year to $40.2 million, exceeding expectations, driven by 41% software revenue growth. Adjusted EBITDA was $1.8 million.
- For full year 2017, revenue increased 27% to $162.5 million with software revenue up 36%. Adjusted EBITDA reached $13.1 million.
- The company has a solid customer base and value proposition with a 95%+ software maintenance renewal rate and strong competitive win rate. Profitability and cash flow are expanding.
Verisk provides forward-looking statements and notes regarding non-GAAP financial measures in its investor materials. The statements relate to future events or financial performance that involve risks and uncertainties. The notes provide supplemental non-GAAP financial information and explain why the company believes these measures provide useful information to investors. Verisk has a strong track record of revenue growth, leading margins, and returning capital to shareholders through share repurchases and acquisitions.
Verisk Analytics held an investor day on December 1, 2015 to discuss its strategy and growth opportunities. The presentation included forward-looking statements and notes on the use of non-GAAP financial measures. It outlined Verisk's core competencies of large-scale data integration, multi-tier imaging, geo-location capabilities, stochastic modeling, and localization. Verisk believes these competencies combined with its unique data assets, domain expertise, and customer relationships position it for continued growth. Wood Mackenzie CEO Stephen Halliday then introduced Wood Mackenzie and how it complements Verisk in the energy and natural resources sectors.
The document discusses Verisk's global opportunities in the insurance industry. It highlights Verisk's focus on growing globally through organic opportunities and acquisitions. Verisk has a global team organized to succeed and pursues growth opportunities through products like Sequel and tuck-in acquisitions. Verisk is well positioned for future global growth in the insurance industry.
This document provides an investor presentation by Asanko Gold Inc. It summarizes the company's world-class asset base in Ghana, which includes over 7.9 million ounces of measured and indicated gold resources across six deposits. It highlights the company's successful construction and start-up of its mining operations, which are exceeding production guidance. The presentation outlines Asanko's plans for further near-term organic growth through exploration success and a phased expansion to increase annual gold production to over 450,000 ounces per year by 2022.
- Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies for central nervous system indications.
- They are developing novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) for indications like Tourette Syndrome and Mild Cognitive Impairment.
- For Tourette Syndrome, they are combining THC with PEA in a proprietary combination therapy called THX-TS01 that has begun Phase II clinical trials based on a 505(b)(2) regulatory pathway.
- For Mild Cognitive Impairment, they are developing an "Ultra-Low Dose THC" therapy called THX-ULD
Vocera investordeck may 12 2017 needhamvocera2016ir
The document discusses Vocera's investor review presentation. It notes that Vocera sees significant growth opportunities through expanding into new clinical areas, new user types, and international markets. It also highlights Vocera's strong financial performance in recent years with recurring revenue growing to 60% of sales and adjusted EBITDA margins expanding. The presentation aims to showcase Vocera as an attractive investment due to its large market opportunity and ability to leverage its operating model.
The document provides an investor review for Vocera Communications. It discusses Vocera's position as a leader in clinical communication and workflow solutions. It highlights Vocera's growth opportunities through continued customer and market expansion. Vocera aims to simplify healthcare professionals' work through its secure communication platform and integration capabilities. The review outlines Vocera's strong financial performance with recurring revenue streams and expanding profitability.
Vocera investordeck july august 2017 webvocera2016ir
The document provides an investor review for Vocera Communications. It discusses Vocera's position as a leader in clinical communication and workflow solutions. It notes Vocera's growth opportunities in large healthcare system deals, expanding existing customers, new product areas like EHR integration, and international markets. Financial highlights show strong revenue growth of 23% recently and expanding profitability and cash flow, with guidance of $6.5-10.5 million in adjusted EBITDA for 2017.
Vocera investordeck september 2017 for webvocera2016ir
The presentation discusses Vocera's investor opportunity. It notes that Vocera has become a recognized leader in clinical communication and workflow solutions. It also highlights Vocera's strong growth, operating leverage, and expanding profitability. The presentation provides visibility into Vocera's revenue for the remainder of 2017 and outlines the company's strategy to drive continued growth in key areas like software, new customers, and international expansion.
Vocera investordeck march 2018 for webvocera2016ir
The document is an investor presentation for Vocera Communications:
- It provides forward-looking statements and discusses risks to the company's projections.
- Vocera has transitioned from a badge-centric point product to a software-centric complete communication solution for healthcare facilities.
- Their platform aims to improve patient outcomes, operational efficiencies, patient experience, and the caregiver experience through enhanced communication.
- Vocera has a large market opportunity in healthcare facilities globally and sees potential for continued growth.
This presentation discusses MedReleaf's forward-looking statements and non-IFRS measures, provides an overview of the company's operations and facilities, highlights its financial and operational performance to date, and outlines its growth strategies and milestones for the next 18 months. Key points include that MedReleaf has achieved over 80% market share in the Canadian medical cannabis market, has expanded production capacity through a new facility, and aims to leverage its expertise internationally and participate in the potential Canadian recreational cannabis market.
Vocera investordeck october 2017 for webvocera2016ir
The document provides an investor review for Vocera Communications. It discusses Vocera's position as a leader in clinical communication and workflow solutions. It highlights Vocera's growth opportunities, including further penetrating existing health system customers, building momentum across new products, and expanding into new international markets. The review also summarizes Vocera's financial highlights, including strong revenue growth, solid recurring revenue streams, expanding profitability, and a strong balance sheet.
This investor presentation by Alteryx, a provider of self-service data analytics software, contains forward-looking statements and discusses Alteryx's business model, competitive advantages, growth opportunities, and financial results. Alteryx has experienced strong revenue growth, currently has over 2,500 customers across various industries, and believes it is well-positioned in a large and growing market. The presentation outlines Alteryx's vision to make data analytics accessible to business users and data scientists through an easy to use and comprehensive platform.
Vocera Communications held an investor presentation in January 2019 at the JP Morgan Healthcare Conference. The presentation highlighted Vocera's mission to simplify and improve lives in healthcare, its strategic evolution from communications to a complete clinical workflow platform, and its significant operating leverage and target operating model. Vocera also discussed its large market opportunity, product innovations, and success with large health systems.
Alteryx is a leading provider of self-service data analytics software. It has experienced strong growth, with over $100 million in TTM revenue and 56%+ year-over-year growth. Alteryx has a large and diverse customer base of over 2,800 customers across various industries. It has a land and expand business model, with a dollar-based net revenue retention rate of over 120%. Alteryx provides an intuitive and comprehensive platform for data preparation, blending, analysis, and sharing. Its solution addresses the growing need for self-service analytics and helps organizations overcome the limitations of traditional methods.
The document is an investor day presentation from Verisk that discusses the company's business strategy and outlook. It provides the following key points:
1. Verisk serves the property and casualty insurance industry across the insurance lifecycle, from product development to actuarial analysis, underwriting, claims management, and portfolio analysis.
2. Verisk provides data-driven solutions that help insurers improve profitability, including predictive modeling, policy language, and loss cost advisory information.
3. By-peril rating for homeowners insurance, which separates policy premiums by risk type, has allowed insurers using this approach to increase market share and lower loss ratios compared to competitors.
MedReleaf is a top licensed producer of medical cannabis in Canada, with a market share of 82% of the total volume sold. The company has a strategy of focusing on pharmaceutical, beverage, and consumer product opportunities to capitalize on the growth of the legal cannabis market. MedReleaf operates a fully licensed indoor cultivation facility in Markham, Ontario and has completed expansion to a new 210,000 square foot facility in Bradford, Ontario that will increase production capacity significantly. Management is focused on profitability, innovation, and international growth opportunities to continue leading the medical cannabis industry in Canada.
Vocera investordeck november 2017 web (1)vocera2016ir
The document discusses Vocera's investor review presentation. It highlights Vocera's position as a recognized leader in clinical communication and workflow solutions. It also summarizes Vocera's opportunity for continued growth, including expanding within existing hospital systems, penetrating new customers, building momentum for new products, and pursuing attractive international markets. The presentation outlines Vocera's diversified revenue streams and trajectory of strong revenue growth coupled with improving adjusted EBITDA.
The document discusses Vocera Communications' investor review presentation. It highlights Vocera's position as a recognized leader in clinical communication and workflow solutions. It also summarizes Vocera's opportunity for continued growth, including expanding within existing hospital systems, penetrating new customer accounts, and pursuing international markets. Vocera sees potential to build on its software portfolio and reach new types of healthcare facilities and users.
The document is an investor presentation by Vocera Communications. It summarizes Vocera's business, including its mission to simplify and improve lives in healthcare, its strategic evolution from communications devices to a complete clinical workflow platform, and its opportunities for growth. It highlights Vocera's strong financial performance with increasing revenue, expanding gross margins, and significant operating leverage. The presentation also outlines Vocera's target operating model and potential to drive further value through leveraging its platform across care settings.
This document contains forward-looking statements from a company regarding plans, expectations, estimates and growth opportunities. It notes that forward-looking statements involve risks and uncertainties. The document also discusses safe harbors under securities laws that provide protection for forward-looking statements. Finally, it notes that actual results could differ from what is stated in the forward-looking statements.
This document is an investor presentation for AMN Healthcare that provides an overview of the company. Some key points:
- AMN Healthcare is a leader and innovator in total talent solutions for healthcare, providing staffing, workforce solutions, leadership and physician search, and talent management services.
- Over 60% of AMN's revenue comes from managed services programs (MSPs) where they provide comprehensive staffing and workforce solutions to health systems.
- AMN has transformed from primarily a diversified staffing company in 2008 to a strategic partner providing a full spectrum of innovative workforce solutions to major health systems in 2022.
- They aim to become the total talent solutions partner for clients by enhancing their digital
Marpai is an AI tech company revolutionizing the self-funded health plan
market representing over $1 trillion in health claims, $20 billion in
administrative fees, and 95 million Americans. Just as Netflix, Amazon,
Uber, and Tesla use artificial intelligence to transform and lead industry
sectors, Marpai (pronounced Mar-pay) is using deep learning, the most
advanced artificial intelligence, to transform health plan administration
for companies who self-fund their health plans. As a next-generation
TPA (Third Party Administrator) using SMART technology (deeplearning powered), Marpai’s mission is to save lives, improve lives, and
radically reduce the costs of healthcare for employers and plan
members.
Similar to Vocera investordeck may 15 2018 web (18)
Vocera ir master_ may 2019 web-convertedvocera2016ir
- The document is an investor presentation from Vocera Communications that discusses the company's strategic evolution towards enabling a real-time healthcare system.
- It highlights Vocera's opportunity for growth in the large global market for clinical communications, its success implementing solutions at major health systems, and its diversified revenue model with recurring revenue streams.
- The presentation also outlines Vocera's progress in achieving operating leverage through improved gross margins and declining operating expenses as a percentage of revenue, as well as its target operating model with even higher margins and adjusted EBITDA.
- The document is an investor presentation from Vocera Communications that discusses the company's strategic evolution towards enabling a real-time healthcare system.
- It highlights Vocera's opportunity for growth in the large global market for clinical communications, its success implementing solutions at major health systems, and its diversified revenue model with recurring revenue streams.
- The presentation also outlines Vocera's progress in achieving operating leverage through improved gross margins and declining operating expenses as a percentage of revenue, which has driven increased adjusted EBITDA in recent years.
- The document is an investor presentation from Vocera Communications that discusses the company's mission, strategic evolution, opportunities for growth, and financial performance.
- Vocera aims to simplify and improve lives in healthcare through clinical communication and workflow software. It is transitioning from badge-centric point solutions to a complete clinical platform.
- The company sees opportunities in large global markets, innovation driving growth, and significant operating leverage as scale increases. Financial metrics like gross margin and adjusted EBITDA have improved steadily in recent years.
- The document is an investor presentation that provides an overview of Vocera Communications, including forward-looking statements and financial highlights.
- It discusses Vocera's large and growing market opportunity in healthcare communications, its transition from a badge-centric product to an enterprise software and solutions provider, and recent platform wins that validate its strategy.
- Financial highlights show that Vocera has achieved over 25% revenue growth in 2017 with expanding profitability, a diversified revenue model with over 50% recurring revenues, and a solid customer base and value proposition.
Vocera investordeck web january 2018 (1)vocera2016ir
This document contains forward-looking statements from Vocera Communications regarding their plans, expectations, objectives, and opportunities. It discusses risks and uncertainties related to the forward-looking statements. The document also provides an overview of Vocera's business opportunities in healthcare including improving clinical workflows, patient experience, and caregiver experience. Financial information is presented showing Vocera's historical and projected revenue, gross profit, operating expenses, and adjustments to calculate non-GAAP figures.
The document discusses Vocera's investor review presentation. It notes that Vocera is experiencing strong revenue growth, with 36% year-over-year revenue growth in Q1 2017. Vocera has a solid customer base and value proposition, with a 95%+ software maintenance renewal rate and strong competitive win rate. Vocera is also expanding profitability and cash flow, with 2017 adjusted EBITDA guidance of $5-10 million and $71 million in cash with no debt. The presentation outlines Vocera's opportunities for continued growth in core customers, new software products, new user segments, and international expansion.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
17. Capital Structure Summary
(($March 31, 2018
March 31, 2018
Pro Forma for
Offering
Cash (1) $81.8(1) $211.7 (2)
Total Debt $0.0 $143.8
Notes:
(1) Includes cash, cash equivalents, and short-term investments
(2) Based on $81.8MM cash, cash equivalents and investments as of 3/31/18 plus net offering proceeds of $129.9MM convertible debt issuance
17
$143.8M of Convertible Notes due 2023
• 5-year Non-call life
• Coupon: 1.5%
• Conversion Premium of 60% ($38.94) with
Call Spread
• Effective Cost of Capital with Call Spread:
2.7%